Skip to main content
FDA Updates
Retevmo Receives New FDA Indication for Advanced Solid Tumors with RET Fusion
Read More
FDA Updates
Imfinzi Receives New FDA Indication for Advanced or Metastatic Biliary Tract Cancer
Read More
FDA Updates
Pemazyre Receives New Indication for FGFR1-­Positive Myeloid/Lymphoid Neoplasms
Read More
FDA Updates
Imbruvica Now Also Indicated for Children with Chronic Graft-versus-Host Disease
Read More
FDA Updates
Enhertu First FDA-Approved Drug for HER2-Positive Non–Small-Cell Lung Cancer
Read More
FDA Updates
Enhertu First FDA-Approved Treatment for HER2-Low Breast Cancer
Read More
FDA Updates
Nubeqa Now Indicated for Metastatic Hormone-Sensitive Prostate Cancer
Read More
Original Research, Chemotherapy, Adverse Events, Oncology Pharmacy Programs/Protocols
Impact of Pharmacist Telephone Follow-Up on Chemotherapy-Induced Nausea and Vomiting
Jenny McCabe, PharmD; Amanda Al-Bahou, PharmD, BCOP; Leann Koontz, PharmD, BCPS, BCOP; Linda Linderbeck, PharmD, BCOP; Michael Verbosky, PharmD, BCPS; Michelle Prieto, PharmD
Read More
Practical Issues in Pharmacy Management, Oncology Pharmacy Programs/Protocols, Clinical Trials
Implementation and Evaluation of a Formal Investigational Drug Service at a Community Cancer Center
Colton Zwart, PharmD, BCOP; Aimee Cloud, PharmD, BCOP; Amanda Kogelman, PharmD, BCOP; Claire Boomershine, PharmD, BCOP
Read More
Original Research, Oncology Pharmacy Programs/Protocols, Oral Therapy
Evaluating Institutional Safety Standards Related to Continuing Oral Antineoplastic Medication Use During Hospitalization
Belinda Li, PharmD, BCOP; Laura Beth Parsons, PharmD, BCOP; Darby Siler, PharmD, BCOP; Rachel Matthews, PharmD, BCOP
Read More
Page 46 of 196
Results 451 - 460 of 1953